Phase 2 Study May Be Added to Ongoing Trial of Combo Ovarian Cancer Immunotherapy

Phase 2 Study May Be Added to Ongoing Trial of Combo Ovarian Cancer Immunotherapy
Immunovaccine and Incyte Corporation are expanding their collaboration on a clinical trial, and plan to add a Phase 2 to their ongoing Phase 1b study in advanced ovarian cancer. The open-label Phase 1b trial (NCT02785250) is evaluating the safety and efficacy of Immunovaccine’s lead candidate DPX-Survivac in combination with Incyte’s IDO1 enzyme inhibitor epacadostat and low-dose cyclophosphamide in about 40 patients with recurrent ovarian cancer. DPX-Survivac consists of small fractions of the survivin protein, which are able to trigger an immune response. DPX-Survivac is thought to work by eliciting a toxic T-cell immune response against cells presenting survivin peptides. Survivin, seen as a promising tumor-associated antigen, is broadly over-expressed in most cancer types and promotes tumor growth. It plays an essential role in supporting tumor blood vessel growth and promoting resistance to anti-cancer therapies. Epacadostat is a potent, selective oral inhibitor of IDO1, an enzyme expressed in many cancers that suppresses T-cell response. The study's Phase 2 part will include up to 32 additional patients and also be open label, meaning all enrolled will receive the treatment.  Its goal, the companies said in a press release, will be to evaluate the clinical contribution of ea
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *